Friday, June 23, 2017

Brain Inflammation Linked to OCD, Study Suggests


Brain inflammation appears to be significantly higher in people with obsessive-compulsive disorder (OCD) than those without the condition, according to a study published this week in JAMA Psychiatry

“This finding represents one of the biggest breakthroughs in understanding the biology of OCD, and may lead to novel therapeutic treatments,” senior author Jeffrey H. Meyer, M.D., Ph.D., said in a press release. Meyer is the head of the Neurochemical Imaging Program in Mood and Anxiety at the Centre for Addiction and Mental Health (CAMH) in Toronto. 

A new direction for developing treatments for OCD is welcomed because about one-third of patients with OCD do not adequately respond to current medications, such as antidepressants, according to the authors.

Meyer and colleagues recruited 20 people with OCD and 20 age-matched healthy controls for the study. The participants were all in good physical health, were not taking medications, and were between the ages of 19 and 48. None of the participants had a history of autoimmune disease or neurologic illness or injury. Psychiatric disorders and OCD were confirmed using the Structured Clinical Interview of DSM-IV.

All participants underwent a positron emission tomography (PET) scan, using a fluorine dye to measure a marker of microglial activity in six brain regions (dorsal caudate, orbitofrontal cortex, thalamus, ventral striatum, dorsal putamen, and anterior cingulate cortex). Activated microglia (immune cells) are known to trigger neuroinflammation.

The researchers found that in people with OCD, inflammation was on average 32% higher in these regions than among those without the condition. 

“To our knowledge, this is the first study demonstrating inflammation within the neurocircuitry of OCD,” Meyer and colleagues wrote. “Although pharmaceutical development does not traditionally prioritize OCD, neuromodulatory treatments under development for other diseases associated with microglial activation, such as Alzheimer disease, might be repurposed toward OCD.” 

For related information, see the Psychiatric News article “Report Highlights Alternative Treatment Options for OCD.”

(Image: iStock/JohnnyGreig)

Thursday, June 22, 2017

APA to Senate: Reject Health Care Reform Proposal That Fails to Put Patients First


APA is urging the Senate to reject the health care reform proposal unveiled today by Senate Republicans. A vote on this bill is expected to come as early as next week, before lawmakers break for the July 4 recess.

The proposed Senate bill rolls back Medicaid expansion, caps federal funding for the Medicaid program, and removes protections for people with pre-existing health conditions. 

“Eliminating requirements for coverage of key benefits, including mental health and substance use disorders and other patient protections that are part of the Affordable Care Act, will have detrimental impacts for millions,” APA President-Elect Altha Stewart, M.D., said in a press release issued by APA today. “Mental health is critical to overall health and needs to be equally accessible.”

Among other provisions, APA opposes changes to Medicaid that would result in the loss of coverage for many Americans, including the estimated 2.8 million with substance use disorders and 1.3 million with serious mental illness, who gained coverage for the first time under the expansion of Medicaid under the current law. The proposed changes to Medicaid could also mean fewer resources for fighting the nation’s opioid epidemic. 

“The Senate proposal represents a significant move in the wrong direction, resulting in fewer people having access to insurance, fewer patient protections, and less coverage for essential behavioral health care,” said APA CEO and Medical Director Saul Levin, M.D., M.P.A., in the press release. “We urge the Senate to reject this harmful legislation and start again on a health care bill that puts patients first.”

Before the Senate’s proposal was made public, APA expressed significant reservations about how the bill was being drafted without the input of patient and physician groups. In an all-member email sent Monday night, Levin urged members to act. “Mental health and substance use treatment is a bipartisan issue,” Levin wrote. “Over the years, APA has worked with both sides of the aisle to achieve passage of the Mental Health Parity and Addiction Equity Act in 2008, its expansion to cover mental health and substance use disorders as part of the Affordable Care Act in 2010, and the 21st Century Cures Act in 2016.”

The House version of the bill, according to the Congressional Budget Office (CBO), would leave some 14 million more Americans uninsured next year than under the current law and 23 million more uninsured by 2026. The Senate bill awaits CBO analysis.

Your Voice Counts
APA urges you to contact your senators and speak out against the Senate health care reform bill released today. APA has created a dedicated tool to make it easy for you to voice your opinion via Facebook, Twitter, or phone.


(Image: Mikhail Kolesnikov/Shutterstock)

Wednesday, June 21, 2017

Clonazepam May Reduce Risk of Relapse in Patients With Panic Disorder


While most patients with panic disorder respond to selective serotonin reuptake inhibitors, benzodiazepines, and/or a combination of the two, the risk of relapse after drug discontinuation is known to be high. A study in the Journal of Clinical Psychopharmacology now suggests that patients who take clonazepam may be at a lower risk of relapse than those treated with paroxetine.

The findings were based on an observational, prospective, six-year follow-up study of patients with panic disorder who participated in an open, randomized trial in which they were assigned to take either clonazepam (0.5 mg/d to 2 mg/d) or paroxetine (10 mg/d to 40 mg/d) for eight weeks. Patients who responded to the assigned monotherapy after eight weeks continued this treatment for 34 months; partial or nonresponders were offered a combined treatment with clonazepam and paroxetine. After 34 months in the long-term study, clonazepam and paroxetine were tapered (four months for clonazepam taper, and six weeks for paroxetine taper).

Of the 95 patients who completed the three-year study, 10 failed to achieve remission. The researchers conducted follow-up assessments with the 85 patients who achieved remission at years 1, 2, 3, 5, and 6 following the discontinuation of clonazepam, paroxetine, or a combination of the two. These assessments evaluated the number of panic attacks the patients experienced per month, Clinical Global Impression-Severity (CGI-S) scores, and the 14-item Hamilton Anxiety Rating Scale (HAM-A) scores. (Patients were considered to have relapsed if they were receiving psychotherapy or medication for panic disorder symptoms, had CGI-S scores greater than 1, or had panic attacks in the month preceding the assessment.)

Over the course of the follow-up period, cumulative relapse rates increased from 50% (n=33) at 1 year to 89.4% (n=76) at 6 years. However, one-year relapse rates were lower in patients previously treated with clonazepam (p=0.001) compared with those treated with paroxetine. Similarly, patients treated with clonazepam showed consistently lower relapse rates at 6 years compared with patients who had not taken clonazepam.

According to lead author Rafael C. Freire, M.D., Ph.D., of the Federal University of Rio de Janeiro and colleagues, the study suggests that despite long-term treatment, patients with panic disorder remain at high risk of recurrence when treatment is discontinued. “Treatment with clonazepam appears to protect these patients against relapse, but further studies are needed to support this affirmation,” the authors concluded.

For related information, see the Psychiatric News article “Benzodiazepines: Experts Urge Balance.”

(Image: BCFC/Shutterstock)

Tuesday, June 20, 2017

APA Members Urged to Voice Opposition to Senate Health Bill Today


APA members are urged to contact their U.S. senators to voice opposition to the health care reform bill now being considered in the Senate. Senators are expected to vote on the bill, which is based on the House-passed American Health Care Act (AHCA), by July 4.

The Senate Republican health care overhaul bill would strip 23 million people of their health insurance coverage and cap the Medicaid program—cutting over $880 billion from the program, which is the largest provider of behavioral health services for psychiatric patients. It would also end the guaranteed inclusion of mental health and substance use disorder treatment services in the list of Essential Health Benefits covered under current law.

Members are encouraged to contact their senators by phone, Twitter, or Facebook. A dedicated page on APA’s website will help members make contact with their Senators through these avenues.

In an all-member email delivered last evening, APA CEO and Medical Director Saul Levin, M.D., M.P.A., urged members to act. “Mental health and substance use treatment is a bipartisan issue,” Levin wrote. “Over the years, APA has worked with both sides of the aisle to achieve passage of the Mental Health Parity and Addiction Equity Act in 2008, its expansion to cover mental health and substance use disorders as part of the Affordable Care Act in 2010, and the 21st Century Cures Act in 2016.”

Senate offices track phone messages and respond to social media. “Your calls and action do count,” Levin said. “We ask that you voice opposition to any bill that would negatively impact patients, and we appreciate your standing with us to do what is right for our patients.”

For more information, see the Psychiatric News article “CBO Says Millions of People Could Lose Coverage Under AHCA.”

(Image: flySnow/istock.com)

Monday, June 19, 2017

Study of Pregnant Publicly Insured Women Finds Increase in SGA Use


The use of second-generation antipsychotics (SGAs) by pregnant women enrolled in Medicaid rose more than threefold between 2001 and 2010, according to a report in Psychiatric Services in Advance. In contrast, the proportion of women who received first-generation antipsychotics (FGA) remained stable over the 10-year period.

“To help clinicians and patients make informed treatment decisions, there is an urgent need for further studies in this area to examine adverse pregnancy outcomes associated with maternal use of antipsychotics, in monotherapy or polytherapy, as well as studies examining comparative effectiveness of specific antipsychotic agents among pregnant women,” Yoonyoung Park, Sc.D., of the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital in Boston and colleagues wrote.

Park and colleagues analyzed Medicaid Analytic eXtract (MAX) data (2001–2010) from 1,522,247 pregnancies. MAX contains data on demographic characteristics, hospitalizations, and outpatient visits as well as on medications dispensed by an outpatient pharmacy.

From 2001 to 2010, the number of women who filled at least one prescription for a SGA during pregnancy increased from .4% (n=376) to 1.3% (n=2,044) (p<.001), while the use of FGAs remained stable at about .1%.

The increase in the proportion of women taking SGAs appeared to be driven in part by an increase in quetiapine use, which rose from 0.1% in 2001 to 0.6% in 2010, and aripiprazole, which was introduced in 2002 and was used by 0.4% of women by 2010, the authors noted. 

During the study period, the prevalence of bipolar disorder diagnosis in pregnant women also increased more than threefold (from .7% to 2.5%), while the proportion of pregnant women with bipolar disorder who received antipsychotics increased from 13.6% in 2001 to 23.6% by 2010. The authors noted that the increase in bipolar disorder diagnoses is “consistent with the increase observed for the general population, including children and adolescents.”

Additionally, among the 15,196 women who took antipsychotics at any time during pregnancy, 65.2% also received antidepressants, 24.9% received benzodiazepines, and 22.0% received mood stabilizers; 765 women (5%) received at least one prescription for all four of these drug types at some point during pregnancy.

“Polytherapy with other psychotropic medications, common in this population, deserves more attention with regard to fetal safety,” Park and colleagues wrote. “Because Medicaid pays for close to 50% of all deliveries of babies in the United States, the results reflect the real-world utilization of antipsychotics in a large proportion of pregnant women in the U.S. population.” 

For related information, see the Psychiatric News article “Yes or No: Prescribing Antidepressants to Pregnant Patients,” by Jennifer L. Payne, M.D. 

(iStock/comzeal)

Friday, June 16, 2017

New Drug Shows Promising Results in Treatment of Postpartum Depression


In a small sample of women with severe postpartum depression, infusion of the compound brexanolone resulted in rapid, significant reduction in symptoms, according to a study published online this week in The Lancet.

The findings “demonstrate a substantial treatment effect of brexanolone” in a group of patients “for which there are no currently approved pharmacological therapies,” Steven Kanes, M.D., of Sage Therapeutics and colleagues wrote. Sage Therapeutics funded this research, and assisted in the study design, data collection, data analysis, data interpretation and writing of the report.

For the double-blind, randomized, controlled trial, the researchers assigned 21 women with severe postpartum depression (Hamilton Depression Rating Scale [HAM-D] score of at least 26) to a 60-hour, continuous intravenous dose of brexanolone or placebo. To make the sample as representative as possible, the researchers recruited patients from urban, suburban, and rural settings in the United States to receive treatment at four research sites.

By 60 hours, seven (70%) women had achieved remission (HAM-D total score of ≤7) compared to one (9%) in the placebo group. Furthermore, mean HAM-D scores for the women who received brexanolone remained significantly lower for a follow-up period of 30 days compared with the placebo group.

Brexanolone is an allosteric modulator of both synaptic and extra-synaptic GABA-A receptors. The results support the rationale for targeting GABA-A receptors in the development of therapies for the estimated 10% to 20% of birth mothers who suffer from postpartum depression, wrote the researchers.

“Our findings provide the first placebo-controlled clinical support for the role of extrasynaptic GABA-A receptors in the modulation of mood and affective states in any clinical population,” wrote the authors. A treatment with rapid onset of action is considered important in severe postpartum depression because of the adverse impact of the depression on the mother, infant, and family.

Brexanolone, a formulation of the neuroactive steroid allopregnanolone, was found to be generally well tolerated among the study participants. There were no deaths, serious adverse events, or discontinuations. The most commonly reported adverse events in the brexanolone group were dizziness (two brexanolone-treated subjects; three placebo-treated subjects) and somnolence (two brexanolone-treated subjects; no placebo-treated subjects).

The author of an accompanying commentary published in The Lancet commented on the study’s “potentially important implication for our understanding of the pathophysiology of postpartum mood disorders,” but he also raised questions such as “Is this a treatment for postpartum episodes specifically or could it be used generally in depression?”

Brexanolone is currently being evaluated in a phase 3 clinical program under way at various other sites across the country.

For related information, see the Psychiatric News article “Synthetic Oxytocin May Increase Risk of Postpartum Depression, Anxiety” and the Psychiatric Services article “Collaborative Care for Perinatal Depression Among Socioeconomically Disadvantaged Women: Adverse Neonatal Birth Events and Treatment Response.”

(Image: iStock/SolStock)

Thursday, June 15, 2017

APA Urges Senate to Be Transparent, Inclusive in Crafting ACA Repeal Bill


APA today joined with five other medical associations to raise concerns about how the Senate is developing legislation that would harm patients by repealing and undermining essential health care coverage and patient protections established by the Affordable Care Act (ACA). 

In a letter to Senate Majority Leader Mitch McConnell (R-Ky.) and Senate Minority Leader Charles Schumer (D-N.Y.), the six medical organizations urged the political leaders to “commit to a transparent, deliberate, and accountable process” that allows adequate time for stakeholders to provide input on the impact the proposed legislation would have on patients and their physicians. The letter also calls for public hearings on the proposed bill as well as sufficient time to ensure that the Senate has the Congressional Budget Office (CBO) score on the legislation and other independent analyses available for review well in advance of any vote.

“Proposed legislation revamping our nation’s health care system needs to be worked on in the open, not behind closed doors,” APA President-Elect Altha Stewart, M.D., said in a news release. “We are determined that the voices of patients with mental illness or substance use disorders be heard.”  

The five groups that signed onto the letter with APA were the American Academy of Family Physicians, American College of Physicians, American Osteopathic Association, American Academy of Pediatrics, and the American Congress of Obstetricians and Gynecologists. These groups collectively represent more than 560,000 physicians and medical students. 

APA was part of the same coalition of medical organizations that had expressed strong opposition to the American Health Care Act (AHCA), which the House of Representatives passed on May 4. 

Late last month, the CBO released its score of the AHCA, which it projected would leave some 14 million more Americans uninsured next year than under the current law and 23 million more uninsured by 2026. APA had responded to the news immediately at the time, renewing its call for the Senate to reject the ACA replacement bill in favor of a bipartisan solution. 

This week, APA CEO and Medical Director Saul Levin, M.D., M.P.A., reiterated that message. “We are willing to work with lawmakers on both sides of the aisle in crafting health care legislation that provides adequate coverage to Americans,” he said in a news release. “Allow us to lend our expertise to this important issue. It is crucial that any legislation include mental health and substance use disorder treatment.”

(Image: Mikhail Kolesnikov/Shutterstock)

Wednesday, June 14, 2017

Lithium Found to Decrease Suicide Risk in Bipolar Patients


Lithium appears to have a protective effect against suicide in patients with bipolar disorder—an effect that was not seen in patients taking valproate, according to a study in AJP in Advance. While previous studies have suggested that lithium treatment reduces risk of suicide, whether the same was true of valproate was less clear.

“Our results, in conjunction with existing literature, indicate that in patients with bipolar disorder and suspected suicidal intentions, lithium should be considered as a suicide preventive strategy, with a balance between efficacy and tolerability,” Jie Song, Ph.D., of the Karolinska Institutet and colleagues wrote.

For the study, the researchers relied on Swedish population-based registers to track outcomes in individuals with bipolar disorder between October 1, 2005, and December 31, 2013. Among the 51,535 patients with bipolar disorder identified, a total of 10,648 suicide-related events occurred in 4,643 individuals (9.0%) during the follow-up period.

When the researchers compared periods when patients were taking either lithium or valproate with periods they were not, they found a 14% reduced rate of suicide-related events for periods when patients were on lithium compared with when they were not (hazard ratio, 0.86); this change was not seen in patients who received valproate treatment (hazard ratio, 1.02). The difference in hazard ratios of suicide-related events between lithium and valproate was statistically significant.

“Since the within-individual analyses drew information exclusively from people who attempted suicide during follow-up, our results demonstrated that the association between lithium and reduced suicide-related events existed even among a high-risk population, which is unlikely to be studied in randomized, controlled trials,” the authors wrote. “Future research on the mechanisms behind the association between lithium and suicidal behavior is warranted and could inform the neurobiology of suicidal behavior.”

For related information, see the Psychiatric News article “Lithium Is Regaining Favor Over Anticonvulsants,” by Jonathan Meyer, M.D., of the University of California, San Diego.

(Image: iStock/asiseeit)

Tuesday, June 13, 2017

AMA Calls on Government to Improve Mental Health Care for Children, Families in Detention


The AMA House of Delegates on Monday approved several resolutions aimed at improving the health and mental health care of immigrants and refugees and their families being held in U.S. detention centers. 

At AMA’s annual policymaking meeting in Chicago, delegates approved resolutions that call on the AMA to do the following: 

  • Advocate for the health and mental health care of U.S. children in deportation proceedings against their undocumented parents.
  • Oppose the expansion of family immigration detention in the United States, oppose the separation of parents from their children who are detained while seeking safe haven, and advocate for access to health care for women and children in immigration detention centers.
  • Advocate for protections that prohibit U.S. Immigration and Customs Enforcement (ICE), U.S. Customs and Border Protection, or other law enforcement agencies from using information from medical records to pursue immigration enforcement actions against patients who are undocumented. 
  • Issue a public statement urging the ICE Office of Detention Oversight to revise its medical standards governing the conditions of confinement at detention facilities to meet those set by the National Commission on Correctional Healthcare and track complaints related to substandard health care quality.

“The unpredictable stress and isolation associated with detainment have a significant potential to exacerbate and contribute to mental illness,” Laura Halpin, M.D., Ph.D. (pictured above), a first-year psychiatry resident at UCLA and a member of the Resident and Fellow Section, told physicians during a discussion of the issue. “Federal policymakers and responsible agency officials must ensure that detained individuals receive appropriate mental health treatment.”

Delegates will consider further resolutions today supporting international medical graduate (IMG) physicians who may be affected by President Donald Trump’s executive order barring travel from certain countries. A six-member educational panel on the subject of physicians, health care, and immigration policy at the AMA meeting yesterday agreed that the executive order, though held up in courts, may affect whether physicians and researchers from other countries will want to come to the United States.

For related information, see the Psychiatric News article “Executive Orders Usher in Era of Uncertainty for IMGs, Program Directors.”

(Image: Mark Moran)

Monday, June 12, 2017

Adjunctive Liraglutide Found to Reduce Weight Gain, Metabolic Effects From Clozapine, Olanzapine


Patients with schizophrenia who experience weight gain and metabolic disturbances while taking clozapine or olanzapine may benefit from once-daily adjunctive treatment with the anti-diabetic medication liraglutide, reports a study published June 10 in JAMA Psychiatry.

“In overweight or obese patients with schizophrenia spectrum disorders and prediabetes, 16 weeks of liraglutide as an adjunctive treatment to stable treatment with clozapine or olanzapine significantly improved glucose tolerance and glycemic control. At the end of the trial, the placebo-subtracted body weight loss was 5.3 kg,” wrote Anders Fink-Jensen, D.M.Sc., of the University of Copenhagen and colleagues. Liraglutide is a glucagon-like peptide-1 receptor agonist approved for the treatment of type 2 diabetes and obesity. 

These findings are encouraging for patients taking these antipsychotics, which are among the most effective for treating schizophrenia but also have the greatest risk of cardiovascular and metabolic side effects, according to the authors.

The study included 103 adults aged 18 to 65 who were diagnosed with a schizophrenia spectrum disorder (schizoaffective disorder excluded) and were receiving stable treatment with clozapine or olanzapine. The participants, who all had prediabetes and a body mass index of 27 or greater, were randomly assigned to 16 weeks of once-daily treatment with subcutaneously injected liraglutide (up to 1.8 mg) or placebo provided in prefilled pen injectors. Every four weeks, participants had blood samples obtained; body weight, waist circumference, and blood pressure measured; and adverse events and alcohol consumption recorded. 

After 16 weeks, patients taking liraglutide had a 23% larger reduction in their two-hour plasma glucose level compared with the placebo group. In the liraglutide group, 30 patients (63.8%) changed status from prediabetes to normal glucose tolerance compared with eight (16.0%) in the placebo group.

Additional benefits observed in the liraglutide group included decreased waist circumference, systolic blood pressure, and low-density lipoprotein cholesterol levels.

Patients in the liraglutide group experienced significantly higher rates of nausea (31 of 50 [62%] vs. 16 of 50 [32%]), but these differences diminished over time, the authors noted.

“Altogether, the liraglutide group experienced significantly fewer serious adverse events, with exacerbation of patients’ psychiatric disease being the most common cause, and no differences in quality of life, daily functioning, or psychiatric disease severity were found,” the authors added.

For related information, see the Psychiatric News article “Aripiprazole May Reduce Some Side Effects of Antipsychotics in Women.” 

(Image: forestpath/Shutterstock)

Friday, June 9, 2017

Benzodiazepine Use May Become Long Term When Combined With Antidepressants


The clinician’s decision to start a patient on antidepressants and benzodiazepines at the same time in treating depression should be considered carefully because of potential long-term use and risks associated with benzodiazepines, according to a study published online June 7 by JAMA Psychiatry.

The study found that among adults who started taking an antidepressant simultaneously with benzodiazepine therapy for treatment of depression, 12.3% of new, consistent users (22% of new, sporadic users) became long-term benzodiazepine users, defined as 6 months or longer of continuous use. This outcome was more common among patients with an initial prescription for a longer benzodiazepine days’ supply or long-acting benzodiazepine and recent prescription opioid fills.

Patients with an initial days’ supply of 8 to 15 days, 22 to 35 days, and more than 35 days were more likely to become long-term users than were patients with 1 to 7 days’ supply, the study found. Older adults, patients initiating long-acting benzodiazepines, and patients diagnosed by a psychiatrist compared with a family practitioner also were more likely to become long-time users. The researchers speculated that this type of therapy may be used more with severe depression, but did not measure depression severity in the study.

The researchers used a 2001-2014 claims database of commercially insured adults (aged 18-64 years) with a recent depression diagnosis who began antidepressant therapy and had not used antidepressants or benzodiazepines in the prior year. Of the study’s 765,130 adults (median age, 39 years), 10.6% received the simultaneous antidepressant-benzodiazepine therapy; the proportion of these patients increased from 6.1% in 2001 and peaked at 12.5% in 2012.

An anxiety diagnosis was found to be the strongest determinant of simultaneous use of benzodiazepines with antidepressants—this was true for 24% of new users with a recent unspecified anxiety diagnosis and 39% with a recent panic disorder diagnosis.

“Despite cautions and concerns, benzodiazepines are commonly prescribed during antidepressant treatment … but less is known about the specific practice of simultaneously beginning benzodiazepine therapy with antidepressant therapy,” wrote the authors.

(Image: simarik /iStock)

Thursday, June 8, 2017

APA Calls for Senators to Reject Flawed American Health Care Act, Offers Priorities for Moving Forward


APA and the American Psychological Association this week called on the Senate to “avoid major flaws” in the American Health Care Act (AHCA) and craft a bill that would result in more people having coverage for mental health and substance use treatment.

In a letter to Senate Majority Leader Mitch McConnell (R-Ky.) and Senate Minority Leader Charles Schumer (D-N.Y.) dated June 6, the two mental health associations expressed their reservations with the House bill passed May 4.

“We strongly oppose the American Health Care Act, as recently passed by the House. According to the Congressional Budget Office, the AHCA would result in 14 million more people uninsured in 2018 than under current law, and 23 million more people without insurance by 2016,” wrote APA CEO and Medical Director Saul Levin, M.D., M.P.A., and American Psychological Association CEO and Executive Vice President Arthur C. Evans, Ph.D. “Millions more would lose access to treatment, with mental health and substance use services no longer being covered under their benefit package. This is the wrong direction for our country.”

Levin and Evans called on the Senate to retain Medicaid eligibility for Americans below 138 percent of the federal poverty level and to retain the current Medicaid financing structure, without the use of per capita caps or block grants.

“Low-income and uninsured adults have sharply higher rates of serious mental illness as those with insurance and higher incomes,” they wrote. “Medicaid expansion has been particularly helpful in addressing the opioid epidemic, as illustrated by the 700 percent increase in use of substance use treatment services among Kentucky beneficiaries after the state expanded its Medicaid program, and Medicaid’s coverage of 37 percent of spending on buprenorphine in New York.”

The opioid epidemic illustrates the danger of capping federal Medicaid payments, they said. “Private insurance payments for opioid abuse and dependence services increased by 1,375 percent between 2011 and 2015 (from $32 million to $446 million),” they wrote. “Under a system of Medicaid per capita capped payments, tens of thousands of individuals struggling with opioid addiction would have been denied Medicaid coverage and treatment, and thousands more would have died. … States already have significant flexibility in tailoring their Medicaid programs, and can be provided more flexibility without capping federal payments.”

Levin and Evans urged the Senate to also continue to require plans to cover an essential health benefits package that includes mental health and substance use disorder services and behavioral health treatment, and to prohibit insurers from charging higher premiums for people with pre-existing conditions. Further, the pair emphasized the importance of continued investment in research and programs, including retaining the Prevention and Public Health Fund.

“Our nation cannot afford to go back to the days when insurers selectively enrolled individuals to avoid financial responsibility for needed services. Nor can we afford to return to viewing mental health and substance use services as optional,” the leaders wrote. “Rather, we must further reduce the uninsured rate, develop integrated systems of care, and continue to foster an environment in which health plans compete on how efficiently and effectively they can provide services.”

Write Your Senators and Urge Them to Start Over on AHCA

APA members are urged to contact their senators to express opposition to the AHCA and instruct the Senate to set aside the House bill and start over on new legislation that does not put at risk health care for people with mental health/substance use disorders. To make such communication quick and easy, visit the APA Advocacy Center.

(Image: Mikhail Kolesnikov/Shutterstock)

Wednesday, June 7, 2017

Prohibiting Psychiatric Patients From Owning Guns Misses Mark, Study Suggests


Prohibiting individuals with a history of psychiatric hospitalization from purchasing firearms alone appears unlikely to significantly reduce the number of victims of gun violence, according to a study in Psychiatric Services in Advance.

The multistate study of state prison inmates found that those with a history of psychiatric hospitalization represented a small proportion of violent gun offenders. “Contrary to media portrayals, persons with a history of hospitalization were less likely than those without such a history to target strangers and were no more likely to engage in public shootings or to have multiple victims,” wrote Aaron Kivisto, Ph.D., of the University of Indianapolis.

Kivisto analyzed data from the 2004 Survey of Inmates in State Correctional Facilities, a survey of a nationally representative sample of state prison inmates. Of the 14,499 inmates interviewed at 287 state prisons between October 2003 and May 2004, 6,535 (45%) were incarcerated for violent offenses, and 1,589 (24%) used a firearm in the commission of a crime. A total of 838 gun-violence perpetrators, defined as those incarcerated for a violent offense during which they fired a gun, had data available regarding psychiatric hospitalization prior to incarceration.

Kivisto found that those with a history of psychiatric hospitalization represented just 1 in 8 violent gun offenders and accounted for only 13% of overall gun violence victims. Moreover, 75% of violent gun offenders who did have a history of psychiatric hospitalization obtained firearms from sources not required by federal law to conduct background checks. 

“Central to understanding the potential public health impact of current [gun] policy efforts, such as the NICS [National Instant Criminal Background Check System] Improvement Act aimed at increasing states’ reporting of individuals prohibited from purchasing firearms for mental health reasons, is the recognition that such policies hinge both on the relative contribution of persons with mental illness to the problem of gun violence and on the potential reach of federal regulations to deter at-risk individuals from obtaining firearms,” Kivisto wrote. “The study’s findings suggest that such efforts face challenges on both fronts.” 

Prior hospitalization alone as a variable for predicting violence is far too non-specific, said Jeffrey Swanson, Ph.D., a professor of psychiatry and behavioral sciences at Duke University and expert on gun violence and mental illness, who was not involved with this study. However, he noted that previous studies have shown that there are subgroups within the population of individuals with prior psychiatric hospitalization—especially those who were involuntarily hospitalized and those with a prior history of violence—who may be at higher risk for dangerousness. Swanson emphasized that mental illness is correlated far more highly with suicide by firearms than with violence against others. 

“The real challenge when balancing risks and rights [to gun ownership] is to focus not on mental illness, per se, but on risk factors related to dangerousness to self or others,” Swanson told Psychiatric News

For related information, see the Psychiatric News article “Gun Violence Reduction Possible With Combined, Varied Actions.”

(Image: iStock/Allkindza)

Tuesday, June 6, 2017

FDA Approves Two-Month Dose of Aristada for Treatment of Schizophrenia

Clinicians will soon be able to offer patients with schizophrenia the option to extend the amount of time between injections of the atypical antipsychotic Aristada (aripiprazole lauroxil). The Food and Drug Administration (FDA) yesterday approved a two-month dose of Aristada for the treatment of schizophrenia.

Aristada, manufactured by Alkermes, was first approved by the FDA in October 2015, with dosages for use every four to six weeks. In August 2016, Alkermes submitted a supplemental New Drug Application (sNDA) to the FDA for a two-month dosing interval of Aristada. The application was based on the results of an open-label trial that compared outcomes in 140 patients with stable schizophrenia who were randomized to receive 441 mg aripiprazole once per month, 882 mg aripiprazole every six weeks, or 1,064 mg aripiprazole every two months.

“Results from the study showed that the 1,064-mg dose of aripiprazole achieved therapeutically relevant plasma concentrations of aripiprazole with a PK [pharmacokinetics] profile that supports dosing once every two months. The most common adverse event for the two-month dosing interval was injection site pain,” the company reported at the time.

“Aristada is now FDA approved in four doses and three dosing-duration options (441 mg, 662 mg, or 882 mg once monthly; 882 mg once every six weeks; and 1,064 mg once every two months) and can be initiated at any dose or interval, offering an unprecedented range of flexibility to patients and health care providers,” according to a press release issued by Alkermes today.

“The availability of an antipsychotic that can be initiated prior to hospital discharge and provide therapeutic levels of medication for two months will be a welcome new treatment option for health care providers, caregivers, and patients,” Joseph McEvoy, M.D., the I. Clark Case Distinguished Chair in Psychotic Disorders at Augusta University and professor emeritus of psychiatry and behavioral health at Duke University Medical Center, said in the Alkermes press release.

According to Alkermes, the two-month dose of the medication is expected to be available in mid-June.

For related news, see the Psychiatric News article “Study Finds Aripiprazole Lauroxil Carries Low Risk of Metabolic Side Effects.”

For related information on long-acting injectables, see the Psychiatric Services article “Hospital Readmission Rates Among Patients With Schizophrenia Treated With Long-Acting Injectables or Oral Antipsychotics.”

(Image: iStock/Ca-ssis)

Monday, June 5, 2017

Chronic Pain May Accelerate Memory Decline, Study Reports


Older adults troubled by persistent pain may be at a greater risk of rapid memory decline, according to a study published today in JAMA Internal Medicine.

“Whereas it is known that chronic pain is associated with poorer cognitive performance in cross-sectional studies, this study newly demonstrates accelerated memory decline and increased probability of developing dementia year-on-year at a population level,” wrote Elizabeth Whitlock, M.D., of the University of California, San Francisco, and colleagues. 

Whitlock and colleagues analyzed data collected as part of the Health and Retirement Study (HRS)—a nationally representative cohort of community-dwelling older adults who undergo detailed in-person or telephone interviews every two years. The researchers focused on adults who were 62 years or older in 2000 and answered pain and cognition questions in 1998 and 2000; those reporting being “often troubled by moderate or severe pain” both years were classified as having “persistent pain.” Participants were followed until death, dropout, or evaluation in 2012.

Of the 10,065 adults included in the sample, 1,120 (10.9% of the weighted sample) reported persistent pain at baseline. Participants reporting persistent pain had more depressive symptoms, a greater prevalence of limitations in activities of daily living, and more comorbid medical conditions than those not experiencing pain. 

“Over time, participants with persistent pain experienced a 9.2% more rapid decline in memory score. This translated to a relative 11.8% to 15.9% increased risk of inability to manage medications or finances independently at the end of 10 years, compared with age-adjusted HRS peers,” Whitlock and colleagues wrote. Additionally, “population-level dementia probability increased 7.7% faster in those with persistent pain compared with those without.”

The authors concluded, “For the elderly, maintenance of cognition is crucial for quality of life and functional independence. … Elucidating the nature of the relationship between pain and cognitive decline is the first step toward developing strategies to mitigate it.”

For related information, see the Psychiatric News article “New Dementia Measures Address Disclosure of Diagnosis to Patients.”

(Image: Richard Lyons/Shutterstock)

Friday, June 2, 2017

Early Signs of Post-TBI Aggression, Depression May Predict Long-Term Challenges


The presence of aggression and new-onset depression within the first three months of a traumatic brain injury (TBI) may predict how likely it is a person will continue to experience post-TBI aggression over the course of the year, finds a study published this week in the Journal of Neuropsychiatry and Clinical Neurosciences.

“The implication of this is that critical assessment of aggression via evaluation of psychosocial and psychiatric disease burden in the early TBI period can allow for early interventions to potentially prevent progression of aggressive behavior later,” wrote lead author Durga Roy, M.D., of Johns Hopkins University School of Medicine and colleagues. Additionally, the “findings suggest that identification and treatment of depression within the first three months of TBI may reduce the burden of disease that ensues from aggression within the first year postinjury.”

For the study, Roy and colleagues assessed psychiatric symptoms and psychosocial functioning in 103 adults with first-time TBI over 12 months. Overall rates of aggression were 34.3% at three months, 41.1% at six months and 38.0% at 12 months. Verbal aggression was the predominant manifestation, while physical aggression (whether on self, others, or objects) was negligible.

Poor social functioning at three months was also found to be associated with aggression at 12 months. Post-TBI cognitive deficits, substance abuse, and frontal lobe injuries did not show any association with subsequent aggression, however.

“Future studies should focus on effective early screening for new-onset depression after TBI and early psychosocial interventions to improve psychosocial functioning,” the authors concluded.

To read more about this topic, see the Psychiatric News article “Sertraline May Help Prevent Depression Following Traumatic Brain Injury.

(Image: decade3d/Shutterstock)

Thursday, June 1, 2017

Recovery-Oriented Cognitive Therapy Benefits Patients With Schizophrenia


Recovery-oriented cognitive therapy (CT-R)—a therapeutic approach that emphasizes a patient’s personal treatment goals—can lead to enduring improvements in low-functioning individuals with schizophrenia, reports a study published today in Psychiatric Services in Advance.

Paul M. Grant, Ph.D., of the University of Pennsylvania and colleagues randomly assigned 60 adults with schizophrenia or schizoaffective disorder to 18 months of CT-R plus standard treatment or standard treatment alone. Standard treatment consisted minimally of antipsychotic medication, but most in this group received some additional services from the local community mental health center. Researchers who were blind to the treatment groups evaluated the study participants at the start of the trial and again 6, 12, 18, and 24 months later.

The researchers found that even though CT-R ended at 18 months, global functioning in the CT-R group remained superior to that in the standard treatment group at 24 months. The CT-R group also showed lower scores for negative symptoms (avolition and apathy) and for positive symptoms compared with participants receiving standard treatment.

“The findings presented here show that these improvements over baseline were maintained across the follow-up period when therapy was withdrawn, supporting the notion that CT-R produces an enduring change in beliefs and skills that enables individuals to continue to maintain gains without their therapist,” Grant and colleagues wrote.

Those with less chronic illness began to show improvement sooner, some as early as six months, with the most prominent benefits evident at the end of active treatment at 18 months. “[T]hose with greater chronicity showed reliable improvements, but they did so later (at 24 months), suggesting that clinicians should not give up on these individuals when it seems that they are not improving as quickly as hoped,” the authors added. “More intensive treatment might quicken their recovery response.”

The CT-R treatment consisted of engaging and establishing a connection with the patient, for example, through music, singing, dancing, or taking a walk, and then working collaboratively with the patient to identify personal, meaningful, and valued goals for the future, such as finding a job, reconnecting with family, developing relationships, and pursuing independent living in the community. Therapists used the cognitive model to help participants overcome obstacles, such as low energy, hallucinations, and disorganization, within a goal-directed framework with personalized treatment targets. Later sessions focused on consolidating gains and preventing relapse.

For related information, see the Psychiatric News article “Psychosocial Treatments Found Effective for Early Psychosis.”

(Image: iStock/Portra)

Disclaimer

The content of Psychiatric News does not necessarily reflect the views of APA or the editors. Unless so stated, neither Psychiatric News nor APA guarantees, warrants, or endorses information or advertising in this newspaper. Clinical opinions are not peer reviewed and thus should be independently verified.